Trinity Biotech (Trinity Biotech) Debt-to-EBITDA

: -4.32 (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Trinity Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.81 Mil. Trinity Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $65.21 Mil. Trinity Biotech's annualized EBITDA for the quarter that ended in Sep. 2023 was $-15.53 Mil. Trinity Biotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -4.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Trinity Biotech's Debt-to-EBITDA or its related term are showing as below:

TRIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.89 Med: -3.13 Max: 52.72
Current: -2.54

During the past 13 years, the highest Debt-to-EBITDA Ratio of Trinity Biotech was 52.72. The lowest was -5.89. And the median was -3.13.

TRIB's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs TRIB: -2.54

Trinity Biotech Debt-to-EBITDA Historical Data

The historical data trend for Trinity Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

-5.89

-5.52

52.72

11.07

-5.09

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA																-2.05	-3.62	-6.08	-1.18	-4.32

Competitive Comparison

For the Diagnostics & Research subindustry, Trinity Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech Debt-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Debt-to-EBITDA falls into.

Trinity Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Trinity Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.886	+	70.314)	/	-14.191
	=	-5.09

Trinity Biotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.81	+	65.205)	/	-15.528
	=	-4.32

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

Trinity Biotech (NAS:TRIB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Trinity Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.